ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Grant Review: NIH Names Members To New Clinical Oncology Review Panel

February 26, 1999

RFA For Patterns Of Care Study in Elderly Issues

January 14, 1983

Centers’ Problems Get Increasing Attention From Staff, Advisors

August 20, 1976

DCT Board Approves Management Support, Drug Storage Concepts

March 3, 1989

Hawaii Epidemiology Studies Offer Opportunities For Major Impact On Cancer Incidence, Survival

January 4, 1985

How Low Can You Go? ODAC Accepts Retrospective Study for Accelerated Approval

September 30, 2011